icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
BpQEE3AQ9eEXqECb